RECRUITING

Study of Dextromethorphan in OCD and Related Disorders

Talk to us

Conditions

Obsessive-Compulsive DisorderIllness Anxiety DisorderBody Dysmorphic DisordersSomatic Symptom DisorderOCDBDDIADSSDFluoxetineDextromethorphan

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Official Title

Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study

Quick Facts

Study Start:2022-01-20
Study Completion:2025-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04899687

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
  2. * Living within California
  3. * Capacity to provide informed consent
  1. * Current bipolar disorder or psychotic disorder
  2. * Active moderate or severe substance use disorder, lifetime severe substance use disorder
  3. * Pregnant or nursing women
  4. * Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
  5. * Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start

Contacts and Locations

Study Contact

Pavithra Mukunda, MS
CONTACT
650 497 2578
ocdresearch@stanford.edu

Principal Investigator

Peter J van Roessel, MD PhD
PRINCIPAL_INVESTIGATOR
Stanford University

Study Locations (Sites)

Stanford University
Stanford, California, 94304
United States

Collaborators and Investigators

Sponsor: Stanford University

  • Peter J van Roessel, MD PhD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-01-20
Study Completion Date2025-12-01

Study Record Updates

Study Start Date2022-01-20
Study Completion Date2025-12-01

Terms related to this study

Keywords Provided by Researchers

  • OCD
  • BDD
  • IAD
  • SSD
  • Fluoxetine
  • Dextromethorphan

Additional Relevant MeSH Terms

  • Obsessive-Compulsive Disorder
  • Illness Anxiety Disorder
  • Body Dysmorphic Disorders
  • Somatic Symptom Disorder